Allergy Therapeutics
Manufacturing pause takes it toll on revenuesAllergy Therapeutics
On the starting blocks towards key data expected in 2023Allergy Therapeutics
Key data on track, return to growth expected next yearAllergy Therapeutics
Solid commercial performance with major R&D upsideAllergy Therapeutics
FDA green lights VLP Peanut vaccine Phase I trialAllergy Therapeutics
Commercialising and developing a differentiated portfolioAllergy Therapeutics
Positive top line G309 results for Grass MATA MPLAllergy Therapeutics
FY21 results show continued strong growthAllergy Therapeutics
VLP Peanut heading towards US Phase I studiesAllergy Therapeutics
Biomarker data confirm VLP Peanut hypoallergenicity